Medical Journals Need Taste Of Their Own Medicine, FDA’s Gottlieb Says
Executive Summary
Medical journals need to take measures to expedite providing up-to-date information to physicians, FDA Deputy Commissioner for Scientific & Regulatory Affairs Scott Gottlieb said
You may also be interested in...
VIGORous Debate Continues In NEJM Over Propriety Of Merck’s Vioxx Study
Merck's Vioxx VIGOR trial results do not need to be corrected, authors of the study assert in letters to the editors of the New England Journal of Medicine Feb. 22
FDA Advisory Committees Need Better Conflict Of Interest Procedures – NEJM
FDA should publish the names and background information of proposed advisory committee members in advance of scheduled meetings, a New England Journal of Medicine editorial recommends
Clinical Trial Registry Policy Will Be Flexible For Phase II, Journal Editors Say
Medical journal editors will apply a case-by-case analysis in determining whether to publish data from Phase II studies that have not been listed in public clinical trial registries, the International Committee of Medical Journal Editors said as the July 1 deadline for trial registration approaches